The tentative approval by the FDA is through the President’s Emergency Plan for AIDS Relief (PEPFAR) program and is supposed to ease regulatory authority submissions, production and distribution in low- and middle-income countries.
The FDA has granted tentative approval for Viatris’ abacavir/dolutegravir/lamivudine for oral suspension to treat HIV-1 infection in children. It is the generic of ViiV Healthcare’s Triumeq PD, which the FDA approved in March 2022.
The tentative approval is through the President’s Emergency Plan for AIDS Relief (PEPFAR) program. Viatris has signed a licensing agreement for pediatric dolutegravir from the Medicines Patent Pool and development agreement with ViiV Healthcare and the Clinton Health Access Initiative for producing and distributing the fixed-dose combination of abacavir/ dolutegravir/lamivudine. The tentative approval eases regulatory authority submissions, production and distribution across 123 low- and middle-income countries.
The World Health Organization recommends abacavir/dolutegravir/lamivudine as a preferred first-line regimen for pediatric patients. According to the Joint United Nations Program on HIV/AIDS, about 660,000 children living with HIV, which works to about approximately 4\0% of the estimated total 1.5 million children living with HIV , did not receive antiretroviral (ARV) therapy in 2022.
“The approval of this single tablet regimen – the fixed-dose combination of abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg — will reduce the pill burden for children living with HIV,” Rakesh Bamzai, president of India, Emerging Asia & Access Markets at Viatris, said in a press release.
Abacavir/dolutegravir/lamivudine is a fixed-dose combination containing two nucleoside reverse transcriptase inhibitors (NRTIs) and integrase strand transfer inhibitor (INSTI). NRTIs interfere with the action of the reverse transcriptase enzyme and INSTI interferes with the action of integrase enzyme to prevent the virus from replicating.
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More
Trump Budget Axes CDC HIV Prevention, Shifts Care, Experts Warn of Risks
June 10th 2025Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.
Read More
Most HIV Patients Trust Their Providers But Don’t Always Feel Heard, Survey Says
May 27th 2025Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.
Read More